miR‑181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1

Lu,Fei; Zhang,Jingru; Ji,Min; Li,Peng; Du,Yahui; Wang,Hongchun; Zang,Shaolei; Ma,Daoxin; Sun,Xiulian; Ji,Chunyan

doi:10.3892/ijo.2014.2390

miR‑181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1

Authors:
- Fei Lu
- Jingru Zhang
- Min Ji
- Peng Li
- Yahui Du
- Hongchun Wang
- Shaolei Zang
- Daoxin Ma
- Xiulian Sun
- Chunyan Ji
View Affiliations

Affiliations: Department of Hematology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China, National Key Lab of Otolaryngology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
Published online on: April 16, 2014 https://doi.org/10.3892/ijo.2014.2390
Pages: 383-392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) remains the major cause of disease relapse and poor prognosis in adults with acute myeloid leukemia (AML). Emerging evidence shows that drug resistance not only exists against conventional chemotherapeutic drugs, but also limits the efficacy of new biological agents. Therefore, it is important to elucidate the mechanisms through which AML patients develop drug resistance. MicroRNAs have been shown to play an important role in regulating the chemotherapy resistance in AML. A detailed understanding of the mechanisms of microRNA that are clinically relevant in AML may enhance our ability to predict and overcome drug resistance. Here, we demonstrated, for the first time, that miR‑181b was decreased significantly in human multidrug-resistant leukemia cells and relapsed/refractory AML patient samples. Overexpression of miR‑181b increased the sensitivity of leukemia cells to cytotoxic chemotherapeutic agents and promoted drug-induced apoptosis. Moreover, miR‑181b inhibited HMGB1 and Mcl-1 expression by direct binding to their 3'-untranslated regions. In addition, HMGB1 was expressed at high levels in relapsed/refractory AML patients and suppression of HMGB1 via RNA interference sensitized multidrug-resistant leukemia cells to chemotherapy and induced apoptosis. In conclusion, these results provide a strong rationale for the development of miR‑181b-based therapeutic strategies for the enhancement of efficacy in AML treatment.

View Figures

View References

1.	Estey EH: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 14:476–479. 2000. View Article : Google Scholar : PubMed/NCBI
2.	Chen Y, Tang Y, Guo C, Wang J, Boral D and Nie D: Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 83:1112–1126. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Nagano H, Tomimaru Y, Eguchi H, et al: MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 43:1066–1072. 2013.PubMed/NCBI
6.	Croce C: Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
7.	Feng DD, Zhang H, Zhang P, et al: Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 15:2164–2175. 2011. View Article : Google Scholar
8.	Li QJ, Chau J, Ebert PJ, et al: miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 129:147–161. 2007. View Article : Google Scholar : PubMed/NCBI
9.	de Yebenes VG, Belver L, Pisano DG, et al: miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 205:2199–2206. 2008.PubMed/NCBI
10.	Wang B, Hsu SH, Majumder S, et al: TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Bisso A, Faleschini M, Zampa F, et al: Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 12:1679–1687. 2013. View Article : Google Scholar : PubMed/NCBI
12.	Lu Y, Roy S, Nuovo G, et al: Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 286:42292–42302. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Zhu W, Shan X, Wang T, Shu Y and Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Marton S, Garcia MR, Robello C, et al: Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 22:330–338. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Visone R, Veronese A, Rassenti LZ, et al: miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 118:3072–3079. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Li S, Moffett HF, Lu J, et al: MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 6:e169562011. View Article : Google Scholar : PubMed/NCBI
17.	Visone R, Veronese A, Balatti V and Croce CM: MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget. 3:195–202. 2012.PubMed/NCBI
18.	Dore LC, Amigo JD, Dos Santos CO, et al: A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci USA. 105:3333–3338. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Wang R, Wang ZX, Yang JS, Pan X, De W and Chen LB: MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Bian HB, Pan X, Yang JS, Wang ZX and De W: Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 30:202011. View Article : Google Scholar : PubMed/NCBI
21.	Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Wang J, Tian X, Han R, et al: Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
23.	Ragusa M, Majorana A, Statello L, et al: Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther. 9:3396–3409. 2010. View Article : Google Scholar
24.	Ji M, Li J, Yu H, et al: Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. Br J Haematol. 145:648–656. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Xiang L, Li M, Liu Y, et al: The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Ann Hematol. 92:1063–1069. 2013. View Article : Google Scholar
26.	Li Z, Huang H, Li Y, et al: Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119:2314–2324. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Garzon R, Garofalo M, Martelli MP, et al: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA. 105:3945–3950. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 26:5078–5087. 2008. View Article : Google Scholar
29.	Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 358:1919–1928. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Zhi F, Cao X, Xie X, et al: Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One. 8:e567182013. View Article : Google Scholar : PubMed/NCBI
31.	Li H, Hui L and Xu W: miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 44:269–277. 2012. View Article : Google Scholar : PubMed/NCBI
32.	Bai H, Cao Z, Deng C, Zhou L and Wang C: miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol. 138:595–602. 2012. View Article : Google Scholar
33.	Andersson U and Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 29:139–162. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
35.	Kang R, Tang DL, Cao LZ, Yu Y, Zhang GY and Xiao XZ: High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell. Zhonghua Er Ke Za Zhi. 45:329–333. 2007.(In Chinese).
36.	Liu L, Yang M, Kang R, et al: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 25:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Xie M, Kang R, Yu Y, et al: Enhancive effect of HMGB1 gene silence on adriamycin-induced apoptosis in K562/A02 drug resistance leukemia cells. Zhonghua Xue Ye Xue Za Zhi. 29:549–552. 2008.(In Chinese).
38.	Kozopas KM, Yang T, Buchan HL, Zhou P and Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 90:3516–3520. 1993. View Article : Google Scholar : PubMed/NCBI
39.	Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC and Pellecchia M: A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 1:e402010. View Article : Google Scholar : PubMed/NCBI
40.	Kaufmann SH, Karp JE, Svingen PA, et al: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 91:991–1000. 1998.PubMed/NCBI
41.	Kasper S, Breitenbuecher F, Heidel F, et al: Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J. 2:e602012. View Article : Google Scholar : PubMed/NCBI
42.	Zhu DX, Zhu W, Fang C, et al: miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
43.	Zhan Z, Li Q, Wu P, et al: Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy. 8:109–121. 2012. View Article : Google Scholar : PubMed/NCBI